Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Koreaopen access
- Authors
- Lee, Sang-Haka; Song, Woo-Hyukb; Jeong, Myung Hoc; Hur, Seung-Hod; Jeon, Dong Woone; Jeung, Wonju; Anselm K Gitt; Martin Horack; Ami Vyas; Dominik Lautsch; Baishali Ambegaonkar; Philippe Brudi; 장양수
- Issue Date
- Sep-2019
- Publisher
- 한국지질동맥경화학회
- Keywords
- Cholesterol; Hydroxymethylglutaryl-CoA reductase inhibitors; Acute coronary syndrome; Coronary artery disease; Dyslipidemias
- Citation
- Journal of Lipid and Atherosclerosis, v.8, no.2, pp 242 - 251
- Pages
- 10
- Indexed
- SCOPUS
KCICANDI
- Journal Title
- Journal of Lipid and Atherosclerosis
- Volume
- 8
- Number
- 2
- Start Page
- 242
- End Page
- 251
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2594
- DOI
- 10.12997/jla.2019.8.2.242
- ISSN
- 2287-2892
2288-2561
- Abstract
- Objective: The aim of this study was to evaluate under target rates of low-density lipoprotein-cholesterol (LDL-C) in Korean patients with stable coronary artery disease (CAD) or an acute coronary syndrome (ACS) in real world practice. Methods: Dyslipidemia International Study II was an international observational study of patients with stable CAD or an ACS. Lipid profiles and use of lipid-lowering therapy (LLT) were documented at enrollment, and for the ACS cohort, 4 months follow-up was recommended. Rates of under target LDL-C as per European guidelines, were evaluated, and multivariate regression was performed to identify predictive factors of patients presenting under the target. Results: A total of 808 patients were enrolled in Korea, 500 with stable CAD and 308 with ACS. Of these, 90.6% and 52.6% were being treated with LLT, respectively. In the stable CAD group, 40.0% were under target LDL-C, while in ACS group, the rate was 23.7%. A higher statin dose was independently associated with under target LDL-C in both groups (OR, 1.03; p=0.046 [stable CAD] and OR, 1.05; p=0.01 [ACS]). The mean statin dosage (atorvastatin equivalent) was 17 mg/day. In the 79 ACS patients who underwent the follow-up examination, the LDL-C under target rate rose to 59.5%. Conclusion: Only a minority of patients with stable CAD or ACS were under their target LDL-C level at enrollment. The statin dose was not sufficient in the majority of patients. These results indicate a considerable LLT gap in Korean patients with established CAD. © 2019 The Korean Society of Lipid and Atherosclerosis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Cardiology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.